These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26974375)

  • 101. Synthesis of somatostatin mimetics based on 1-deoxynojirimycin.
    Chagnault V; Lalot J; Murphy PV
    ChemMedChem; 2008 Jul; 3(7):1071-6. PubMed ID: 18418832
    [TBL] [Abstract][Full Text] [Related]  

  • 102. A light-activated beta-turn scaffold within a somatostatin analog: NMR structure and biological activity.
    Ulysse LG; Chmielewski J
    Chem Biol Drug Des; 2006 Feb; 67(2):127-36. PubMed ID: 16492160
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Catechol: A minimal scaffold for non-peptide peptidomimetics of the i + 1 and i + 2 positions of the beta-turn of somatostatin.
    Mowery BP; Prasad V; Kenesky CS; Angeles AR; Taylor LL; Feng JJ; Chen WL; Lin A; Cheng FC; Smith AB; Hirschmann R
    Org Lett; 2006 Sep; 8(20):4397-400. PubMed ID: 16986909
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Recent advances of chroman-4-one derivatives: synthetic approaches and bioactivities.
    Emami S; Ghanbarimasir Z
    Eur J Med Chem; 2015 Mar; 93():539-63. PubMed ID: 25743215
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Chromones as a privileged scaffold in drug discovery: a review.
    Keri RS; Budagumpi S; Pai RK; Balakrishna RG
    Eur J Med Chem; 2014 May; 78():340-74. PubMed ID: 24691058
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances.
    Reis J; Gaspar A; Milhazes N; Borges F
    J Med Chem; 2017 Oct; 60(19):7941-7957. PubMed ID: 28537720
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Chroman-4-one and chromone based somatostatin β-turn mimetics.
    Fridén-Saxin M; Seifert T; Malo M; da Silva Andersson K; Pemberton N; Dyrager C; Friberg A; Dahlén K; Wallén EA; Grøtli M; Luthman K
    Eur J Med Chem; 2016 May; 114():59-64. PubMed ID: 26974375
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Somatostatin sst4 ligands: chemistry and pharmacology.
    Crider AM; Witt KA
    Mini Rev Med Chem; 2007 Mar; 7(3):213-20. PubMed ID: 17346214
    [TBL] [Abstract][Full Text] [Related]  

  • 109. 2-pyridylthioureas: novel nonpeptide somatostatin agonists with SST4 selectivity.
    Liu S; Crider AM; Tang C; Ho B; Ankersen M; Stidsen CE
    Curr Pharm Des; 1999 Apr; 5(4):255-63. PubMed ID: 10101224
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Drug design at peptide receptors: somatostatin receptor ligands.
    Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
    J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
    [TBL] [Abstract][Full Text] [Related]  

  • 111. [Recent advances in the study of structure modification of somatostatin].
    Gong X; Han X; Wang DX
    Yao Xue Xue Bao; 2006 Nov; 41(11):1027-33. PubMed ID: 17262942
    [No Abstract]   [Full Text] [Related]  

  • 112.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 113.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 114.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 115.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 6.